AF1q is an oncogenic factor involved in leukemia development, thyroid tumorigenesis, and breast cancer metastasis.
Introduction
Homo sapiens ALL1-fused gene chromosome 1q (af1q) gene, which is located in chromosome 1 band 21, was initially identified as a mixed-lineage leukemia fusion partner in patients with an infant acute myelomonocytic leukemia carrying the t(1;11)(q21;q23) translocation (1) . AF1q cDNA encodes a small protein of 90 amino acids with no welldefined functional domains. There were only limited studies for the biological function of AF1q. Overexpression of AF1q was reported in pediatric acute myeloid leukemia (2) , myelodysplastic syndrome (3), and thyroid oncocytic tumors (4) . The gene was also induced in normal human mammary epithelial cells on exposure to carcinogen benzo[a]pyrene (5) . Recently, AF1q was suggested to be a mediator of metastasis promotion in human breast cancer (6) . However, the involvement of AF1q in the drug resistance and apoptosis has not yet been shown.
Drug resistance is a major hindrance encountered in cancer chemotherapy. During tumorigenesis or the course of chemotherapy, alteration of gene expression may occur and influence cellular sensitivity to chemotherapeutic drugs (7) . By reverse transcription-PCR (RT-PCR)-based differential display technique, between the human squamous carcinoma A431 parent (AP) cells and its doxorubicinresistant A10A subline (8) , one of the cDNA clones was found to be down-regulated in A10A cells and have 99% sequence homology with AF1q. By transient transfection, AF1q increased the sensitivity of A431 cells to doxorubicin and also enhanced doxorubicin-induced apoptosis. We therefore hypothesized that AF1q may be involved in the regulation of apoptosis. By constructing the AF1q stable transfectants, we confirmed that AF1q increased the doxorubicin-induced apoptosis in cells through the BAD-mediated mitochondrial apoptotic pathway.
Materials and Methods
Cell Lines, Reagents, and Antibodies Human squamous cell carcinoma AP cells and its doxorubicin-resistant subline A10A cells (8) were cultured in DMEM supplemented with 10% fetal bovine serum and 2 mmol/L L-glutamine (Invitrogen). AN, AQ1, and AQ5 cells were cultured under the same condition as AP cells, except the medium was supplemented with 300 Ag/mL G418 (Calbiochem). Human hepatocellular carcinoma HepG2 cells were cultured in DMEM supplemented with 5% fetal bovine serum and 2 mmol/L L-glutamine; human promyelocytic leukemia HL60 cells were cultured in RPMI 1640 (Invitrogen) supplemented with 20% fetal bovine serum and 2 mmol/L L-glutamine. All cells were incubated in humidified incubator with 10% CO 2 at 37jC. Doxorubicin and Taxol were purchased from Sigma. IFN-a and IFN-g were provided by Biosource International.
The antibodies for Western blot analysis were mouse monoclonal anti-AF1q (Abnova); rabbit polyclonal anti-BAD, anti-BAX, anti-BCL-xL, anti-BCL-2, anti-FAS, anticaspase-3, and goat anti-FADD (Santa Cruz Biotechnology); mouse monoclonal anti-cytochrome c (BD PharMingen); and mouse monoclonal anti-BID and anti-caspase-9 (Stressgen).
MTT Assay Cells were seeded in a 96-well plate for 48 h. After incubation with doxorubicin for 48 h, the cells were incubated with 50 AL of 1 mg/mL MTT (Sigma) in PBS for 3 h. The formazan formed was solubilized by 150 AL DMSO. The absorbance was read at 570 nm using a spectrophotometer (Molecular Devices).
mRNA Differential Display Total RNA was extracted from A431 cells and DNA contamination was removed with MessageClean Kit (GenHunter). Equal amount of RNA from A431 cells was reversely transcribed with oligo(dT) primer 5 ¶-AAGCT-TTTTTTTTTTG-3 ¶ and amplified by PCR using the 5 ¶-arbitrary primer 5 ¶-AAGCTTCTCAACG-3 ¶ provided in the RNAimage kit (GenHunter). The amplified and radiolabeled cDNAs were run in parallel in 6% denaturing polyacrylamide gel. Bands that are unique or differentially expressed were extracted, reamplified, and subcloned into pCR-TRAP cloning vector (GenHunter). After confirmation by Northern blot analysis, the positive clones were sequenced and the sequences were aligned with the Genbank database using BLAST search.
Cloning of AF1q Full-Length cDNA into pcDNA-DEST40 Vector
The I.M.A.G.E. cDNA clone 4108071 was purchased (American Type Culture Collection) and the full-length AF1q cDNA without stop codon sequence was amplified by PCR using the forward primer 5 ¶-CACCATGAGG-GACCCTGTG-3 ¶ and the reverse primer 5 ¶-GAGCAAGTC-CAGTTCGAA-3 ¶. The PCR product was subcloned into the pENT/SD/TOPO gateway vector and then transferred into mammalian expression gateway vector pcDNA-DEST40 using the Gateway technology (Invitrogen) according to the instructions of the manufacturer.
TransientTransfection of Full-Length AF1q cDNA Plasmid and Antisense AF1q Oligonucleotides
For the full-length AF1q cDNA transfection, AF1q-pcDNA/DEST40 plasmid DNA was allowed to form complexes with LipofectAMINE 2000 (Invitrogen) for Mismatch or antisense AF1q oligonucleotides were allowed to form complexes with Oligofectamine (Invitrogen) for 20 min. The sequence of antisense AF1q oligonucleotide is 5 ¶-CTACTCACAGGGTCCCTCAT-3 ¶ and that for the mismatch oligonucleotides is 5 ¶-GTAATCAGACCGTCC-GACAC-3 ¶. After 4 h incubation with the complex, cells were subjected to drug treatment or sample extraction.
Establishment of A431Stable AF1qTransfectants
The full-length AF1q cDNA was subcloned into the expression vector pcDNA3.0 (Invitrogen). The AF1q-pcDNA3.0 and the vector control pcDNA3.0 were transfected into the AP cells with LipofectAMINE 2000 (Invitrogen) using the manufacturer's instructions. After transfection, neomycin-resistant clones were selected in the presence of 600 Ag/mL G418 (Calbiochem). The positive clones were identified by RT-PCR and Western blot analyses. Two positive clones with the highest AF1q expression were selected and named as AP/AF1q-pcDNA3.0 clone 1 (AQ1) and clone 5 (AQ5). The vector control is the cells transfected with empty vector, named as AP/pcDNA3.0 (AN).
ReverseTranscription-PCR Total RNA was extracted by lysing cells with TRI reagent (Molecular Research Center). Total RNA was used to synthesize the first-strand cDNA by MMLV reverse transcriptase (Promega). PCR was then carried out using AF1q-specific forward primer 5 ¶-AACTGGATCTGTCG-GAGC-3 ¶ and reverse primer 5 ¶-GGAGTGGATGCTGG-CAAT-3 ¶. h-Actin was used as the internal control and the primers were 5 ¶-GCGGGAAATCGTGCGTGACATT-3 ¶ and 5 ¶-GATGGAGTTGAAGGTAGTTTCGTC-3 ¶. PCR were done at 94jC for 2 min and 25 amplification cycles of 94jC for 30 s, 55jC for 30 s, and 70jC for 30 s followed by 70jC for 5 min. The amplification products were resolved on 1.5% agarose gel. Intensity of the bands was quantitated by Kodak Digital Science 1D image analysis software. The band intensity was first normalized with that of h-actin, and then normalized to that of the control sample, of which the expression is designated as 1.0. All other primer sequences are available on request.
Quantitative RT-PCR Real-time PCR amplification was done in the ABI 7500 Fast Real-time PCR system using 1Â Power SYBR Green PCR Master Mix (Applied Biosystems). PCR primers for BAD (5 ¶-AGGGAGGGCTGACCCAGAT-3 ¶ and 5 ¶-GGC-GGAAAACCCAAAACTTC-3 ¶) and h-actin (5 ¶-ACACCC-CAGCCATGTACGTT-3 ¶ and 5 ¶-TCACCGGAGTCCAT-CACGAT-3 ¶) were designed by using the Primer Express 3.0 (Applied Biosystems). After the thermal cycling, a DNA dissociation curve was generated to confirm the specificity of the amplification. Relative Standard Curve Method (2 ÀDDCt ) was used to determine the relative mRNA expression of BAD by using h-actin as the reference.
Western Blot Analysis
Cells were lysed in Laemmli's lysis buffer. Protein was then resolved by SDS-PAGE and transferred to Immobilon polyvinylidene difluoride membrane (Millipore). After overnight blocking with 5% nonfat dried milk, the membranes were incubated with primary antibodies for 2 h and then respective horseradish peroxidase-conjugated secondary antibodies at 1:10,000 dilution (Zymed). Signals were developed by using enhanced chemiluminescence detection reagents (Amersham Biosciences) and visualized on X-ray film (Fuji Photo Film). The intensity of the bands was quantitated by Kodak Digital Science 1D image analysis software. The band intensity was first normalized with that of h-actin, and then normalized to that of the control sample, of which the expression is designated as 1.0.
DNA Fragmentation Assay
After drug treatment, the cells were trypsinized and lyzed in lysis buffer (5 mmol/L Tris-HCl, 100 mmol/L EDTA, 1% SDS, and 0.2 mg/mL proteinase K) for 2 h at 45jC. Genomic DNA was extracted by phenol/chloroform/isoamyl alcohol (25:24:1) and precipitated by absolute ethanol at -80jC for 2 h. The DNA pellet then resuspended in Tris-EDTA (pH 8.0) with 0.2 mg/mL RNase A overnight. DNA (40 Ag) was loaded and visualized on a 1.5% agarose gel.
TUNEL Assay Quantitative analysis of DNA fragmentation was assessed by TUNEL assay using TUNEL Label Mix (Roche Applied Science). Cells were fixed with a freshly prepared fixation solution for 1 h at room temperature. After washing twice with PBS, cells were incubated in permeabilization solution for 2 min on ice followed by 50 AL TUNEL reaction mixture for 1 h at 37jC in the dark. Samples were then analyzed by flow cytometry.
Annexin V Binding Assay Cells were trypsinized, washed, and resuspended in Annexin V binding buffer (pH 7.4; 10 mmol/L HEPES, 140 mmol/L NaCl, 5 mmol/L CaCl 2 ). Annexin V-green fluorescent protein and propidium iodide were then added to the cell suspension. After incubation at room temperature for 15 min, cells were analyzed by flow cytometry FACSCanto (BD Biosciences) and the data obtained were analyzed by WinMDI. The BAD small interfering RNA (siRNA) sequence targeting the BAD mRNA was 5 ¶-AAGAAGGGACT-TCCTCGCCCG-3 ¶ (9). The sense and antisense strands of BAD siRNA, together with a negative control siRNA, which is nonhomologous to any known gene sequence, were chemically synthesized by Tech Dragon. The siRNA 
Measurement of Mitochondrial Membrane Potential
Cell were trypsinized, washed, and then stained with 10 Amol/L JC-1 (Molecular Probes) for 30 min at 37jC. The red and the green fluorescent intensities were measured by flow cytometry FACSCanto (BD Biosciences) and the data obtained were analyzed by WinMDI.
Mitochondrial Cytochrome c Release Assay Cells were trypsinized and lysed with lysis buffer (75 mmol/L NaCl, 1 mmol/L NaH 2 PO 4 , 8 mmol/L Na 2 HPO 4 , 250 mmol/L sucrose, 1 mmol/L phenylmethylsulfonyl fluoride, 5 Ag/mL leupeptin, 21 Ag/mL aprotinin, and 12.5 Ag/mL digitonin) for 30 s. Cell debris was removed by centrifugation at 14,000 rpm for 1 min, and protein was resolved in 15% SDS-PAGE. The level of released cytochrome c was detected using standard Western blot analysis protocol as described above.
Results and Discussion

Identification of AF1q Differential Gene Expression by mRNA Differential Display
The doxorubicin-resistant A10A subline was derived from human squamous cell carcinoma AP cells that survived after acute high dosage of 5 Ag/mL followed by 10 Ag/mL doxorubicin. A10A cells were more resistant to doxorubicin compared with the AP cells (Fig. 1A) . Moreover, the level of apoptosis induced by several therapeutic agents [e.g., doxorubicin (Fig. 1A) , Taxol, gradiation, IFN-a, and IFN-g (data not shown)] was also less in the A10A cells. To identify the gene that regulated the resistance, the gene expression profile of AP and A10A cells was compared by RT-PCR-based differential display (Fig. 1B) . Among the cDNA clones identified to have differential expression, one of the cDNA clones was found to be down-regulated in A10A cells and have 99% sequence homology with H. sapiens ALL1-fused gene chromosome 1q (af1q) gene (NM_006818; Fig. 1C) . By Northern blot analysis, the mRNA expression pattern probed by cDNA clones from the differential display (Fig. 1D, left) and that from RT-PCR with AF1q gene-specific primers (Fig. 1D,  right) were similar. It is suggested that AF1q was downregulated in A10A cells.
AF1q Regulation of Doxorubicin-Induced Apoptosis AF1q was identified previously as an important oncogenic factor involved in leukemia development, thyroid tumorigenesis, and breast cancer metastasis (2, 4, 6) . The involvement of AF1q in apoptosis induction has, however, not yet been demonstrated. Refractory to drug-induced apoptosis is one of the ways that may lead to drug resistance in cells. Because AF1q was down-regulated in the drug-resistant A10A cells, we therefore hypothesized that AF1q may play a regulatory role in therapeuticsinduced apoptosis. Transfection of AP cells with antisense AF1q oligonucleotides greatly reduced both mRNA and protein levels of AF1q ( Fig. 2A) and significantly decreased the DNA fragmentation induced by doxorubicin (Fig. 2B , DNA fragmentation assay, and Fig. 2C , TUNEL assay) and other therapeutic agents (e.g., Taxol, g-radiation, IFN-a, and IFN-g; Fig. 2B) . A similar but a lesser effect was observed for doxorubicin-induced apoptosis in A10A cells (Supplementary Fig. S1A ). 1 Apart from A431 cells, AF1q also decreased the doxorubicin-induced apoptosis in human hepatocellular carcinoma HepG2 cells and human promyelocytic leukemia HL60 cells by Annexin V binding assay (Fig. 2C) . On 0.1 Ag/mL doxorubicin treatment, the apoptotic cells (Annexin V-positive) for AP, HepG2, and vector (+) for 24 h and then lysed for RNA or protein extraction. RT-PCR was used to determine the mRNA expression levels of AF1q, BAD, BAX, BID, BCL-2, BCL-xL, FAS, and FADD, whereas Western blot analysis was done to detect the protein levels. *, P < 0.05 (n = 3), significantly different from that with empty vectors. The BAD mRNA (C) and protein (D) levels in A431 AF1q stable transfectants. The relative BAD mRNA and protein levels in AP, AN, AQ1, and AQ5 cells were measured by quantitative RT-PCR and Western blot analyses, respectively. h-Actin was used as the reference. Bars, SD. *, P < 0.05 (n = 3), versus the AN cells.
HL60 cells transfected with mismatch oligonucleotides were 26.2%, 24.1%, and 23.6%, respectively, whereas they were 16.3%, 19.4%, and 13.0%, respectively, for antisense AF1q oligonucleotides. Similar results were observed by the DNA fragmentation assay (data not shown).
To further examine the effect of AF1q on apoptosis induction, the cells were transfected with full-length AF1q cDNA. Transient transfection with full-length AF1q cDNA increased the doxorubicin-induced apoptosis in AP, HepG2, and HL60 cells by both Annexin V binding assay (Fig. 3A) and DNA fragmentation assay (data not shown). Moreover, the AF1q enhancement of doxorubicin-induced apoptosis can also be observed in the AF1q stable transfectants, AQ1 and AQ5 cells; both stable transfectants showed an increase in apoptosis induction on doxorubicin treatment when compared with either AP cells or vector control (AN) cells (Fig. 3B) . The results from both AF1q knockdown and overexpressing experiments therefore suggest that AF1q may play a critical role in doxorubicininduced apoptosis in different human cancer cells. The present study is the first to show the regulatory role of AF1q in the process of apoptosis induction. Although AF1q was identified previously to have oncogenic function, the apoptotic function of AF1q may therefore appear not to be in line with its oncogenic role. However, AF1q may possibly have dual function in the regulation of cell proliferation and apoptosis as that has been reported for the other oncogenes. The transcription factor c-myc is oncogenic when its expression is dysregulated, whereas it also has the ability to trigger apoptosis (10, 11) . H-ras is also oncogene that can promote apoptosis in cells (12, 13) .
AF1q Up-regulation of BAD There are two main apoptotic pathways, the intrinsic (mitochondrial) and extrinsic (death receptor) pathways, which in turn activate the executioner caspases like caspase-3 (14, 15) . The intrinsic apoptotic pathway is mainly regulated by the expressions of proapoptotic and antiapoptotic members of BCL-2 family (16, 17) , whereas the extrinsic pathway involves the binding of death receptor ligands to specific death receptors. To elucidate the molecular mechanism for AF1q regulation of apoptosis, the expressions of some of the BCL-2 family members, FAS and FADD, were examined in AP cells transiently transfected with AF1q full-length cDNA. By RT-PCR Subsequently, the transfected cells were lysed for protein extraction followed by immunoblotting with anti-BAD antibody. The effect of BAD siRNA on doxorubicin-induced apoptosis as measured by DNA fragmentation (B) and Annexin V binding assays (C). After transfection, the cells were treated with 0.1 Ag/ mL doxorubicin for 48 h. For apoptosis measured by DNA fragmentation assay, genomic DNA was extracted and revealed on a 1.5% agarose gel. For Annexin V binding assay, cells were analyzed and plotted as mentioned in Fig. 2C . *, P < 0.05 (n = 3), significantly different from cells transfected with negative control siRNA. C, cells without transfection.
( Fig. 4A) and Western blot analyses (Fig. 4B) , both mRNA and protein levels of proapoptotic BAD were found to be induced (>2-fold) in AP cells transiently transfected with full-length AF1q cDNA, although there are no change in the levels of BCL-2, BCL-xL, BAX, BID, FAS, and FADD. Consistent with the data from transient transfection, BAD was also up-regulated in AF1q stable transfectants (AQ1 and AQ5) as measured by quantitative RT-PCR (Fig. 4C) and Western blot analyses (Fig. 4D) . The results suggested that BAD is likely to be involved in AF1q regulation of apoptosis.
BAD Mediated the Proapoptotic Function of AF1q
To confirm whether BAD is downstream of AF1q in apoptosis regulation, we used BAD siRNA to knock down BAD expression in cells. Transfection with BAD siRNA down-regulated BAD (Fig. 5A ) and at the same time decreased the doxorubicin-induced apoptosis in both AN and AQ5 (AF1q stable transfectants) cells (Fig. 5B and C) . After BAD siRNA transfection, the apoptotic cells (Annexin V-positive) greatly decreased from 18.6% to 11.4% in AN cells and from 24.7% to 10.8% in AQ5 cells on doxorubicin treatment. The results therefore supported that BAD is downstream of AF1q in apoptosis regulation.
BAD is a proapoptotic protein in the mitochondrial mediated apoptosis pathway (18, 19) that involves mitochondrial membrane depolarization and the release of cytochrome c, caspase-9, and caspase-3 activation (20, 21) .
To further confirm the involvement of mitochondrialmediated apoptosis in AF1q-regulated apoptosis, the effect of AF1q on these events was studied. By JC-1 staining, there was a greater shift of the green fluorescence to the right in AF1q stable transfectants (AQ1 and AQ5) than that in the AN cells on doxorubicin treatment (Fig. 6A) . It indicated that doxorubicin-induced mitochondrial depolarization in AF1q stable transfectants was more significant than that in the AN cells. Moreover, the level of cytosolic cytochrome c was much higher in the AQ1 and AQ5 cells than that in the AN cells on doxorubicin treatment (Fig. 6B) , suggesting that AF1q enhanced the release of cytochrome c from the mitochondria into the cytosol. At the same time, greater increases in the levels of active caspase-9 and caspase-3 were also observed in AQ1 and AQ5 cells with doxorubicin when compared with AN cells (Fig. 6C) . Therefore, the results supported that AF1q regulation of apoptosis involved the BAD-mediated mitochondrial apoptotic pathway.
AF1q Regulation of Apoptosis Is Unlikely at the Process of BAD Dephosphorylation
The apoptotic activity of BAD is dependent on its phosphorylation status at Ser 112 , Ser 136 , and Ser 155 (22) . When BAD is phosphorylated on these sites, it forms complex with 14-3-3 proteins and fails to induce apoptosis (22) . Until now, three major kinase pathways have been identified to promote the BAD phosphorylation, mitogenactivated protein kinase/RSK catalyze the phosphorylation caspase-3 activation in A431 cells. Cells were treated with 0.1 Ag/mL doxorubicin for 48 h and then harvested for total protein and probed with caspase-9-or caspase-3-specific antibody. *, P < 0.05 (n = 3). The expression of a specific protein in AQ1 and AQ5 cells is significantly different from that in the AN cells after doxorubicin treatment.
